Stemline Therapeutics - STML Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$11.83
+0 (0.00%)
Get New Stemline Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STML and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STML

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Stemline Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $11.83.

This chart shows the closing price for STML for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Stemline Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/2/2020AegisReiterated RatingBuy
5/5/2020HC WainwrightDowngradeBuy ➝ Neutral$18.00 ➝ $12.50
5/5/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$12.50
5/5/2020Alliance Global PartnersDowngradeBuy ➝ Neutral$14.50 ➝ $12.50
5/4/2020WedbushDowngradeOutperform ➝ Neutral$11.00 ➝ $12.50
5/4/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$10.00 ➝ $12.50
3/27/2020Cantor FitzgeraldReiterated RatingOverweight$18.00 ➝ $10.00
3/26/2020JPMorgan Chase & Co.Lower TargetOverweight$9.00 ➝ $8.00
3/23/2020AegisReiterated RatingBuy$11.00
3/17/2020WedbushLower TargetOutperform$14.00 ➝ $11.00
3/17/2020Piper SandlerLower Target$25.00 ➝ $9.00
3/17/2020HC WainwrightLower TargetBuy$20.00 ➝ $18.00
3/3/2020HC WainwrightReiterated RatingBuy$20.00
1/21/2020HC WainwrightLower TargetBuy$35.00 ➝ $20.00
1/16/2020WedbushLower TargetOutperform$17.00 ➝ $14.00
12/24/2019Cantor FitzgeraldInitiated CoverageOverweight$18.00
12/11/2019HC WainwrightReiterated RatingBuy$35.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Stemline Therapeutics logo
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Read More

Today's Range

Now: $11.83
Low: $11.83
High: $11.83

50 Day Range

MA: $11.83
Low: $11.83
High: $11.83

52 Week Range

Now: $11.83
Low: $3.21
High: $18.22

Volume

1,084 shs

Average Volume

1,524,566 shs

Market Capitalization

$621.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Stemline Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Stemline Therapeutics in the last twelve months:
View the latest analyst ratings for STML.

What is the current price target for Stemline Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Stemline Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Stemline Therapeutics in the next year.
View the latest price targets for STML.

What is the current consensus analyst rating for Stemline Therapeutics?

Stemline Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for STML.

What other companies compete with Stemline Therapeutics?

How do I contact Stemline Therapeutics' investor relations team?

Stemline Therapeutics' physical mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company's listed phone number is 646-502-2311 and its investor relations email address is [email protected]. The official website for Stemline Therapeutics is www.stemline.com. Learn More about contacing Stemline Therapeutics investor relations.